<DOC>
	<DOCNO>NCT00562380</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , AMG-479 , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . PURPOSE : This phase I trial study side effect best dose AMG-479 treating patient advance solid tumor non-Hodgkin lymphoma .</brief_summary>
	<brief_title>AMG-479 Treating Patients With Advanced Solid Tumors Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess safety pharmacokinetics anti-IGF-1R fully human monoclonal antibody AMG-479 ( AMG-479 ) multiple intravenous administration adult patient histologically document advanced solid tumor refractory standard therapy curative therapy available . Secondary - To assess tolerability determine maximum tolerate dose AMG-479 . - To assess tumor glucose metabolism use PET/CT scan tracer fludeoxyglucose F 18 . - To measure insulin-like growth factor receptor ( IGF-1R ) level peripheral blood cell . - To establish whether human anti-human antibody AMG-479 develop patient advance solid tumor . - To measure tumor response modify Response Evaluation Criteria Solid Tumors . Tertiary - To investigate bone turnover marker . - To investigate potential biomarker development biochemical analysis blood cell tumor cell . OUTLINE : This multicenter study . - Part 1 ( dose-escalation ) : Patients receive escalate dos anti-IGF-1R fully human monoclonal antibody AMG-479 ( AMG-479 ) IV 1 hour day 1 , 15 , 29 . Patients evaluate week 8 , demonstrate objective tumor response stable disease continue treatment begin day 57 . Treatment AMG-479 repeat every 2 week absence disease progression unacceptable toxicity . - Part 2 ( randomize dose-expansion ) : Patients randomize one two dose regimen . - Arm I : Patients receive AMG-479 IV 1 hour low dose day 1 . - Arm II : Patients receive AMG-479 IV 1 hour high dose day 1 . Treatment repeat every 14 day absence disease progression unacceptable toxicity . Tumor tissue obtain baseline 4 week study therapy biomarker analysis . Blood drawn periodically biomarker analysis ( insulin-like growth factor [ IGF ] -1 , IGF-binding protein 3 [ IGF-BP3 ] , IGF-1 receptor [ IGF-1R ] , cross-linked c-telopeptides type 1 collagen [ CTx ] , bone-specific alkaline phosphatase [ BSAP ] , tartrate-resistant acid phosphatase [ TRAP5b ] ) pharmacokinetic study . After completion study therapy , patient follow least 4 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically cytologically confirm advanced solid tumor nonHodgkin lymphoma refractory standard treatment curative therapy available Tumor tissue accessible biopsy use minimally invasive procedure must consent undergo biopsy tumor ( part 2 ) Exception patient Ewing family tumor desmoplastic small round cell tumor whose anatomic location would pose increase risk injury due biopsy ( i.e. , bleed pneumothorax ) Willing provide exist and/or future paraffinembedded tumor sample Exclusion criterion : Primary CNS tumor hematological malignancy , nonHodgkin lymphoma Primary hepatic tumor increase risk hepatic tumor , include follow : Hepatitis etiology Alcohol abuse dependency Hepatic adenoma Follicular nodular hyperplasia Autoimmune condition associate biliary tract cancer Alpha 1 antitrypsin deficiency Hemochromatosis History vinyl chloride thorotrast/thorium dioxide exposure History histiocytic ( Kupffer cell ) neoplasia Presence untreated symptomatic CNS metastasis symptoms brain metastasis Presence ascites pleural effusion require medical intervention PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status ≤ 2 Not pregnant nursing Fertile patient must use effective contraception Able provide fast blood sample triglyceride glucose laboratory test Able fast 46 hour fludeoxyglucose F18PET/CT scan Controlled type 1 2 diabetes ( define hemoglobin A1c &lt; 8.0 % fast blood glucose level &lt; 160 mg/dL ) allow part 2 Exclusion criterion : History clinically significant hypoglycemia hyperglycemia ( opinion investigator ) Myocardial infarction within past year Unstable uncontrolled disease/condition relate impacting cardiac function , include follow : Unstable angina Congestive heart failure NYHA class III IV heart disease Uncontrolled hypertension ( diastolic BP &gt; 90 mm Hg systolic BP &gt; 150 mm Hg ) Clinically significant cardiac arrhythmia CTCAE version 3.0 ≥ grade 2 Clinically significant electrocardiogram abnormality History arterial venous ( deep vein ) thrombosis within past year History bleeding diathesis History chronic hepatitis History HIV infection Unable tolerate intravenous administration Known sensitivity mammalianderived product ANC &lt; 1,500/mm^3 ( without filgrastim [ GCSF ] support within past 2 week ) Platelet count &lt; 100,000/mm^3 ( without transfusion within past 2 week ) Hemoglobin &lt; 9 g/dL ( without transfusion within past 4 week ) PT/PTT &gt; 1.5 x upper limit normal ( ULN ) Serum creatinine &gt; 1.5 x ULN AST ALT &gt; 2.5 x ULN Total bilirubin &gt; 1.5 x ULN Urinary protein excretion &gt; 1,000 mg/day ( ≥ 2+ use dipstick analysis ) Any kind disorder compromise ability patient give write informed consent and/or comply study procedures Any comorbid medical condition , sponsor 's investigator 's opinion , may put patient significant risk Known sensitivity product administer dose Unresolved toxicity &gt; grade 1 prior anticancer therapy , exclude alopecia PRIOR CONCURRENT THERAPY : No prior antitumor treatment within past 28 day Palliative externalbeam radiotherapy lesion use RECIST measurement acceptable study symptom management patient stable improve progress At least 30 day since prior concurrent enrollment another clinical trial involve medication No antibody therapy treatment underlying malignancy within past 8 week No concurrent prior anticoagulation therapy , except lowdose warfarin ( &lt; 2 mg/day ) prophylaxis central venous catheter thrombosis No concurrent insulin ( except diabetic patient enrol dose expansion [ part 2 ] study ) No concurrent investigational procedure No concurrent blood bloodproduct transfusions No concurrent herbal medication No concurrent anticancer therapy include chemotherapy hormonal therapy Gonadotropic releasinghormone agonists antagonist allow advanced prostate cancer No major surgery within past month none plan 28 day completion study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>adult desmoplastic small round cell tumor</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>